Corcept Therapeutics (NASDAQ: CORT) presented clinical trial data at the American Diabetes Association's 86th Scientific Sessions showing improved outcomes in patients with difficult-to-control type 2 diabetes and hypercortisolism when treated with Korlym alongside GLP-1 receptor agonists.

The CATALYST trial screened 1,057 patients with difficult-to-control type 2 diabetes and found 24 percent had hypercortisolism. In the treatment phase, 136 patients with hypercortisolism were randomized to receive either Korlym or placebo for 24 weeks. Patients receiving Korlym showed a 1.3 percent reduction in hemoglobin A1c and reductions in body weight of 5.1 kg, body mass index of 1.7 kg/m2, and waist circumference of 5.1 cm compared to placebo.

Among 71 patients taking GLP-1 receptor agonists or tirzepatide, those receiving Korlym demonstrated greater improvements with HbA1c reductions of 1.7 percent, body weight reductions of 6.1 kg, body mass index reductions of 2.0 kg/m2, and waist circumference reductions of 6.5 cm compared to placebo.

The MOMENTUM trial screened 1,086 patients with resistant hypertension and found 27.3 percent had hypercortisolism. The prevalence was higher at 36.6 percent in CATALYST and 32.6 percent in MOMENTUM among patients with HbA1c of 7.5 percent or higher taking three or more blood pressure medications.

The most common adverse events in the CATALYST trial included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea and dizziness.

Korlym is approved for controlling hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not surgical candidates.